公司资料
Integra LifeSciences 股价、新闻与催化剂
- 股票代码:
- IART
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
17.66 USD (-3.71%)
收盘价
最后更新: 2026年8月17日
1.22B USD
市值
股价为何变动
As of Aug 17, 2026, IART closed down 3.71% at $17.66. No new same-company headline was identified in the current news window.
公司概览
Medical Technology Portfolio
Integra LifeSciences develops medical technologies used in neurosurgery, reconstructive surgery and wound care. Its products support procedures in which tissue protection, repair and regeneration are critical to patient outcomes.
Neurosurgical Technologies
The company supplies instruments, implants and systems used in neurosurgery and neurocritical care. These products include technologies for dural repair, intracranial pressure management, tissue ablation and precision surgical access.
Tissue and Wound Reconstruction
Integra’s regenerative-tissue portfolio includes products used for soft-tissue reinforcement, wound closure and surgical reconstruction. SurgiMend is a biologic matrix intended to return to production from the company’s Braintree manufacturing facility.
未来催化剂
- Start of SurgiMend production at the Braintree facility targeted by the end of June 2026.
- Relaunch of SurgiMend expected in the fourth quarter of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。